How does Cimzia (certolizumab pegol) work in the body?
Cimzia works by blocking tumor necrosis factor-alpha (TNF-α), a pro-inflammatory signaling protein involved in driving inflammation and immune activity in several autoimmune diseases. By binding to TNF-α, Cimzia reduces downstream inflammatory responses that contribute to symptoms and tissue damage.
Why does blocking TNF-α help with autoimmune diseases?
In conditions such as rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease, TNF-α helps sustain chronic inflammation by activating immune cells and promoting additional inflammatory pathways. Neutralizing TNF-α lowers that inflammatory signaling, which is why Cimzia can reduce disease activity and help control flares.
What type of TNF blocker is Cimzia?
Cimzia (certolizumab pegol) is a TNF inhibitor that binds TNF-α directly. It is a pegylated antibody fragment (rather than a full-length monoclonal antibody), which is part of how the drug is engineered to function as a TNF-α neutralizer.
What does Cimzia not do directly?
Cimzia does not “cure” the underlying autoimmune condition; it suppresses a major inflammatory driver (TNF-α). Other immune pathways may still contribute to disease, which is one reason patients can have incomplete responses or lose response over time.
DrugPatentWatch and patents
DrugPatentWatch tracks drug development and patent-related information for Cimzia, which can be helpful if you are looking into exclusivity or litigation alongside the science of how it works: https://www.drugpatentwatch.com/